Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo

Valle-Solís, Aura Erazo; Miranda-Aguirre, Arturo Pabel; Mora-Pérez, Josué; Pineda-Juárez, Juan Antonio; Gallardo-Valencia, Luis Ernesto; Santana, Liberio; Cervantes-Sánchez, Guadalupe; Cárdenas-Cárdenas, Eduardo

doi:10.24875/gmm.19005133

Cited by 2 publications

(1 citation statement)

References 16 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast carcinoma is the most frequent type of cancer in women and the second most frequent in the world, according to data from Globocan [ 1 ]. The World Health Organization (WHO) estimates 1.38 million new cases and 458,000 deaths for 2020 [ 2 ]. The National Institute of Statistics and Geography (INEGI) states that breast cancer is the leading cause of death by malignant tumors in Mexican women of 20 years of age or older, and the WHO estimates that 69% of deaths caused by breast carcinoma occur in developing countries [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Molecular Profile of Breast Carcinoma Using Immunohistochemistry Markers in Mexican Women

et al. 2021

View full text Add to dashboard Cite

Background: In Mexico, breast cancer is the leading cause of death by malignant tumors in women aged 20 and older. The World Health Organization estimates that 69% of deaths caused by breast cancer occur in developing countries. Little is known about the prevalence of breast carcinoma in Mexico and its molecular subclassification.Methods: This retrospective cross-sectional study included patients who underwent a mastectomy (single, radical or lumpectomy) or a breast tumor biopsy (core-needle or excisional) from January 2002 to December 2018. The primary purpose of the study was to determine the prevalence and molecular profile of breast in comprehensive cancer center in Mexico and compare our results with those published in the US. This study was approved by our scientific and bioethical committee. Results:The final analysis included 379 patients. The youngest patient was 23 years old and the oldest patient was 89; the mean age at diagnosis was 54.63 years. Patients of 40 years old or younger accounted for 48 of the cases (12.66%) and those older than 40 accounted for 331 of the cases (87.33%). The molecular subclassification showed luminal A subtype in 139 cases (36.67%), luminal B subtype in 143 cases (37.73%), human epidermal growth factor receptor 2-positive carcinomas in 32 cases (8.44%) and triple-negative carcinomas in 65 cases (17.15%). Diabetes mellitus was present in 43 patients (11.34%), hypertension in 78 patients (20.58%), obesity in 82 patients (21.63%) and 66 patients reported being treated with exogenous hormone therapy (17.41%). Conclusions:Breast carcinoma occurs at an earlier age in Mexican women compared to women in the US. Hormone-positive tumors were found to be more prevalent in older patients, while high-grade tumors were more frequently identified in younger patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence and Molecular Profile of Breast Carcinoma Using Immunohistochemistry Markers in Mexican Women

et al. 2021

View full text Add to dashboard Cite

show abstract

Terapias Diana Y Biomarcadores en El Cáncer De Mama: Revisión Bibliográfica

Zaccara Cunha Araújo,

Matias Soares,

Alves de Oliveira

et al. 2024

RECIMA21

View full text Add to dashboard Cite

O câncer de mama é uma das principais causas de morbidade e mortalidade entre as mulheres em todo o mundo, representando um desafio significativo para a saúde pública. Um dos principais avanços na terapia do câncer de mama tem sido o desenvolvimento de terapias-alvo que visam componentes específicos das células tumorais responsáveis pelo crescimento e disseminação do câncer. Objetivo: realizar uma revisão bibliográfica dos avanços mais recentes em terapias-alvo e biomarcadores no câncer de mama. Métodos: Foi realizada uma busca sistemática na literatura científica, utilizando bases de dados como PubMed, Web of Science, Scopus e Google Scholar. Foram incluídos estudos originais e revisões publicados entre 2009 e 2024, em inglês, português ou espanhol, relacionados a terapias-alvo, biomarcadores e câncer de mama. Resultados e Discussão: A análise dos estudos revelou avanços significativos em terapias-alvo, como trastuzumabe e inibidores de CDK4/6, além da importância dos biomarcadores, como Ki-67 e receptores hormonais, na predição de resposta ao tratamento. Destacou-se também o impacto econômico positivo das terapias-alvo e biomarcadores na redução de custos de saúde a longo prazo. Conclusão: As terapias-alvo e biomarcadores representam avanços fundamentais no tratamento do câncer de mama, oferecendo uma abordagem mais personalizada, eficaz e econômica. A contribuição dessas estratégias para a prática clínica e a tomada de decisão ressalta a importância contínua da pesquisa e aplicação dos avanços científicos na oncologia.

show abstract

Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo

Cited by 2 publications

References 16 publications

Prevalence and Molecular Profile of Breast Carcinoma Using Immunohistochemistry Markers in Mexican Women

Prevalence and Molecular Profile of Breast Carcinoma Using Immunohistochemistry Markers in Mexican Women

Terapias Diana Y Biomarcadores en El Cáncer De Mama: Revisión Bibliográfica

Contact Info

Product

Resources

About